Clinical Trial

Evaluation of the Efficacy of QUITOXIL® in Smoking Cessation

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
As part of post-marketing clinical monitoring and with a view to applying for the digital medical device Quitoxil® to be included on the LPPR list, this prospective, multicentre, controlled, randomised clinical trial aims to evaluate the clinical impact of support provided by Quitoxil® as an adjunct to conventional management for patients undergoing smoking cessation who have a tobacco use disorder.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-07-20.
Trial Details
NCT Number NCT07722832
Lead Sponsor KLAVA Innovation
Conditions Tobacco Use Disorder
Enrollment 606 participants
Start Date 2026-10-01
Primary Completion 2028-04-01 (estimated)
Study Completion 2028-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-24